Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Possible mitochondrial dysfunction and its association with antiretroviral therapy use in children perinatally infected with HIV.

Crain MJ, Chernoff MC, Oleske JM, Brogly SB, Malee KM, Borum PR, Meyer WA 3rd, Mitchell WG, Moye JH, Ford-Chatterton HM, Van Dyke RB, Seage Iii GR.

J Infect Dis. 2010 Jul 15;202(2):291-301. doi: 10.1086/653497.

2.

In utero nucleoside reverse transcriptase inhibitor exposure and signs of possible mitochondrial dysfunction in HIV-uninfected children.

Brogly SB, Ylitalo N, Mofenson LM, Oleske J, Van Dyke R, Crain MJ, Abzug MJ, Brady M, Jean-Philippe P, Hughes MD, Seage GR 3rd.

AIDS. 2007 May 11;21(8):929-38.

PMID:
17457086
3.

Nucleoside analogs plus ritonavir in stable antiretroviral therapy-experienced HIV-infected children: a randomized controlled trial. Pediatric AIDS Clinical Trials Group 338 Study Team.

Nachman SA, Stanley K, Yogev R, Pelton S, Wiznia A, Lee S, Mofenson L, Fiscus S, Rathore M, Jimenez E, Borkowsky W, Pitt J, Smith ME, Wells B, McIntosh K.

JAMA. 2000 Jan 26;283(4):492-8.

PMID:
10659875
4.

Pharmacokinetic characteristics of ritonavir, zidovudine, lamivudine, and stavudine in children with human immunodeficiency virus infection.

Fletcher CV, Yogev R, Nachman SA, Wiznia A, Pelton S, McIntosh K, Stanley K.

Pharmacotherapy. 2004 Apr;24(4):453-9.

PMID:
15098798
5.

Drug safety during pregnancy and in infants. Lack of mortality related to mitochondrial dysfunction among perinatally HIV-exposed children in pediatric HIV surveillance.

Lindegren ML, Rhodes P, Gordon L, Fleming P; Perinatal Safety Review Working Group; State and Local Health Department HIV/AIDS Surveillance Programs.

Ann N Y Acad Sci. 2000 Nov;918:222-35.

PMID:
11131709
6.

Lack of long-term effects of in utero exposure to zidovudine among uninfected children born to HIV-infected women. Pediatric AIDS Clinical Trials Group Protocol 219/076 Teams.

Culnane M, Fowler M, Lee SS, McSherry G, Brady M, O'Donnell K, Mofenson L, Gortmaker SL, Shapiro DE, Scott G, Jimenez E, Moore EC, Diaz C, Flynn PM, Cunningham B, Oleske J.

JAMA. 1999 Jan 13;281(2):151-7.

PMID:
9917118
7.
8.

Long-term body fat outcomes in antiretroviral-naive participants randomized to nelfinavir or efavirenz or both plus dual nucleosides. Dual X-ray absorptiometry results from A5005s, a substudy of Adult Clinical Trials Group 384.

Dubé MP, Komarow L, Mulligan K, Grinspoon SK, Parker RA, Robbins GK, Roubenoff R, Tebas P; Adult Clinical Trials Group 384.

J Acquir Immune Defic Syndr. 2007 Aug 15;45(5):508-14.

PMID:
17589373
9.

Lack of definitive severe mitochondrial signs and symptoms among deceased HIV-uninfected and HIV-indeterminate children < or = 5 years of age, Pediatric Spectrum of HIV Disease project (PSD), USA.

Dominguez K, Bertolli J, Fowler M, Peters V, Ortiz I, Melville S, Rakusan T, Frederick T, Hsu H, D'Almada P, Maldonado Y, Wilfert C; PSD Consortium. Perinatal Safety Review Working Group.

Ann N Y Acad Sci. 2000 Nov;918:236-46.

PMID:
11131710
10.

A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.

Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, Eron JJ Jr, Feinberg JE, Balfour HH Jr, Deyton LR, Chodakewitz JA, Fischl MA.

N Engl J Med. 1997 Sep 11;337(11):725-33.

11.

Combination therapy with stavudine (d4T) plus didanosine (ddI) in children with human immunodeficiency virus infection. The Pediatric AIDS Clinical Trials Group 327 Team.

Kline MW, Van Dyke RB, Lindsey JC, Gwynne M, Culnane M, Diaz C, Yogev R, McKinney RE Jr, Abrams EJ, Mofenson LM.

Pediatrics. 1999 May;103(5):e62.

PMID:
10224206
12.

Osteonecrosis of the hip (Legg-Calvé-Perthes disease) in human immunodeficiency virus-infected children.

Gaughan DM, Mofenson LM, Hughes MD, Seage GR 3rd, Ciupak GL, Oleske JM; Pediatric AIDS Clinical Trials Group Protocol 219 Team.

Pediatrics. 2002 May;109(5):E74-4.

PMID:
11986480
13.

Incidence of cancer in children perinatally exposed to nucleoside reverse transcriptase inhibitors.

Benhammou V, Warszawski J, Bellec S, Doz F, André N, Lacour B, Levine M, Bavoux F, Tubiana R, Mandelbrot L, Clavel J, Blanche S; ANRS-Enquête Périnatale Française.

AIDS. 2008 Oct 18;22(16):2165-77. doi: 10.1097/QAD.0b013e328311d18b. Erratum in: AIDS. 2012 May 15;26(8):1047. Carbillon, François F [corrected to Carbillon, L].

PMID:
18832880
14.

Efficacy of zidovudine compared to stavudine, both in combination with lamivudine and indinavir, in human immunodeficiency virus-infected nucleoside-experienced patients with no prior exposure to lamivudine, stavudine, or protease inhibitors (novavir trial).

Joly V, Flandre P, Meiffredy V, Brun-Vezinet F, Gastaut JA, Goujard C, Remy G, Descamps D, Ruffault A, Certain A, Aboulker JP, Yeni P; Novavir Study Group.

Antimicrob Agents Chemother. 2002 Jun;46(6):1906-13.

15.

Lack of evidence of mitochondrial dysfunction in the offspring of HIV-infected women. Retrospective review of perinatal exposure to antiretroviral drugs in the Perinatal AIDS Collaborative Transmission Study.

Bulterys M, Nesheim S, Abrams EJ, Palumbo P, Farley J, Lampe M, Fowler MG; Perinatal Safety Review Working Group.

Ann N Y Acad Sci. 2000 Nov;918:212-21.

PMID:
11131707
16.

Combination nucleoside analog reverse transcriptase inhibitor(s) plus nevirapine, nelfinavir, or ritonavir in stable antiretroviral therapy-experienced HIV-infected children: week 24 results of a randomized controlled trial--PACTG 377. Pediatric AIDS Clinical Trials Group 377 Study Team.

Wiznia A, Stanley K, Krogstad P, Johnson G, Lee S, McNamara J, Moye J, Jackson JB, Mendez H, Aguayo R, Dieudonne A, Kovacs A, Bamji M, Abrams E, Rana S, Sever J, Nachman S.

AIDS Res Hum Retroviruses. 2000 Aug 10;16(12):1113-21.

PMID:
10954886
17.

Disease progression in HIV-infected patients treated with stavudine vs. zidovudine.

Justice AC, Stein DS, Fusco GP, Sherrill BH, Fusco JS, Danehower SC, Becker SL, Hansen NI, Graham NM; CHORUS Program Team.

J Clin Epidemiol. 2004 Jan;57(1):89-97.

PMID:
15019015
18.

Two-year outcomes of children on non-nucleoside reverse transcriptase inhibitor and protease inhibitor regimens in a South African pediatric antiretroviral program.

Jaspan HB, Berrisford AE, Boulle AM.

Pediatr Infect Dis J. 2008 Nov;27(11):993-8. doi: 10.1097/INF.0b013e31817acf7b.

PMID:
18818556
19.

Results of the ALBI trial: a randomized comparison of stavudine/didanosine, zidovudine/lamivudine and alternating treatment in antiretroviral-naive patients.

Molina JM, Chêuc G, Ferchal F, Journot V, Pellegrin I, Sombardier MN, Rancinan C, Cotte L, Madelaine I, Debord T, Decazes JM; ALBI (ANRS 070) Study Group.

Antivir Ther. 1999;4 Suppl 3:71-4.

PMID:
16021874
20.

Human immunodeficiency virus infection in children.

Hoernle EH, Reid TE.

Am J Health Syst Pharm. 1995 May 1;52(9):961-79. Review.

PMID:
7641035

Supplemental Content

Support Center